Search

Mark William Surber

from San Diego, CA
Age ~56
Get Report
Also known as:
Mark W Surber, Mark V Surber, Mark W Suber
Phone and address:
4746 Edison St, San Diego, CA 92117
(619) 990-4938
Related to:
Sumeet Dharkar, 80Ajay Dharkar, 80Sumeet Dharkar, 43Anuroopa Dharkar, 76
Connected to:
Barbara R Surber, 91Catherine L Surber, 74Danny M Surber, 80Deborah V Surber, 55Edward D Surber, 48Gina B Surber, 49Guy L Surber, 57Irene M Surber, 93Jessica L Surber, 45Joy Surber, 34

Mark Surber Phones & Addresses

  • 4746 Edison St, San Diego, CA 92117 (619) 990-4938 (619) 275-5211
  • 4747 Edison St, San Diego, CA 92117
  • Coronado, CA
  • Gaithersburg, MD
  • Long Beach, CA
  • 4746 Edison St, San Diego, CA 92117 (619) 957-7808

Education

Degree: High school graduate or higher

Resumes

Resumes

Mark Surber Photo 1

Mark Surber

View page
Location:
United States
Mark Surber Photo 2

Mark Surber

View page
Location:
Greater San Diego Area
Industry:
Pharmaceuticals

Business Records

Name / Title
Company / Classification
Phones & Addresses
Mark W. Surber
President
Windward Pharma Inc
12636 High Blf Dr, San Diego, CA 92130
Mark W. Surber
President
BAY PARK SOLUTIONS
Nonresidential Building Operator
171 C Ave STE C, Coronado, CA 92118

Publications

Us Patents

Immunogenic Minicells And Methods Of Use

View page
US Patent:
7396822, Jul 8, 2008
Filed:
Apr 26, 2004
Appl. No.:
10/832000
Inventors:
Roger A. Sabbadini - Lakeside CA, US
Neil Berkley - San Diego CA, US
Mark Surber - San Diego CA, US
Assignee:
Vaxiion Therapeutics, Inc. - San Diego CA
International Classification:
A61K 48/00
C12N 15/63
US Classification:
514 44, 424 931, 4353201
Abstract:
The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.

Aerosolized Fluoroquinolones And Uses Thereof

View page
US Patent:
7838532, Nov 23, 2010
Filed:
May 18, 2006
Appl. No.:
11/436875
Inventors:
Mark W. Surber - San Diego CA, US
Keith A. Bostian - Atherton CA, US
Michael N. Dudley - San Diego CA, US
Olga Lomovskaya - Mill Valley CA, US
David C. Griffith - San Marcos CA, US
Assignee:
Mpex Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 31/00
A61K 31/44
A61K 31/4412
A61K 33/00
A61K 33/06
A61K 33/14
A61K 33/26
A61K 33/30
A01N 25/00
A01N 25/02
A01N 25/06
A01N 59/08
US Classification:
514294, 514279, 424405, 424602, 424641, 424646, 424677, 424681, 424682
Abstract:
Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.

Rhamnose-Inducible Expression Constructs And Methods

View page
US Patent:
7871815, Jan 18, 2011
Filed:
Oct 11, 2006
Appl. No.:
11/580095
Inventors:
Roger A. Sabbadini - Lakeside CA, US
Neil Berkley - San Diego CA, US
Mark W. Surber - Coronado CA, US
Assignee:
Vaxiion Therapeutics, Inc. - San Diego CA
International Classification:
C12N 15/00
C07H 21/02
C07H 21/04
A61K 48/00
US Classification:
4353201, 536 231, 536 241, 514 44 R
Abstract:
Disclosed herein is a rhamnose-inducible expression vector.

Enhancement Of Tigecycline Potency Using Efflux Pump Inhibitors

View page
US Patent:
7879795, Feb 1, 2011
Filed:
Aug 1, 2007
Appl. No.:
11/832626
Inventors:
Tomasz Glinka - Cupertino CA, US
Keith Bostian - Atherton CA, US
Olga Lomovskaya - Mountain View CA, US
Mark Surber - San Diego CA, US
Dongxu Sun - Cupertino CA, US
Assignee:
Mpex Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 38/00
US Classification:
514 12
Abstract:
Disclosed herein are Efflux Pump Inhibitor (EPI) compounds that can be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens. The EPI compounds are soft drugs which exhibit a reduced propensity for tissue accumulation. It is demonstrated that the EPIs can be used to increase the potency, decrease bacterial resistance and development of bacterial resistance, and increase killing effectivness of tigecycline. Also disclosed are methods of treatment and pharmaceutical compositions for co-administering tigecylcine with an EPI.

Bacterial Efflux Pump Inhibitors And Methods Of Treating Bacterial Infections

View page
US Patent:
7893020, Feb 22, 2011
Filed:
May 20, 2005
Appl. No.:
11/134147
Inventors:
Tomasz Glinka - Cupertino CA, US
Keith Bostian - Atherton CA, US
Mark Surber - San Diego CA, US
Olga Lomovskaya - Mountain View CA, US
Dongxu Sun - Cupertino CA, US
Assignee:
Mpex Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 38/00
US Classification:
514 12
Abstract:
This invention relates to the field of antimicrobial agents and more specifically it relates to Efflux Pump Inhibitor (EPI) compounds to be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens. The EPI compounds are soft drugs which exhibit a reduced propensity for tissue accumulation. The invention includes novel compounds useful as efflux pump inhibitors, compositions and devices comprising such efflux pump inhibitors, and therapeutic use of such compounds.

Use And Administration Of Bacterial Efflux Pump Inhibitors

View page
US Patent:
7947741, May 24, 2011
Filed:
Mar 16, 2005
Appl. No.:
11/082745
Inventors:
Keith Bostian - Atherton CA, US
Tomasz Glinka - Cupertino CA, US
Olga Lomovskaya - Mountain View CA, US
Mark Surber - San Diego CA, US
Assignee:
Mpex Pharmaceuticals, Inc. - San Diego CA
International Classification:
A01N 37/52
A61K 31/155
US Classification:
514637, 514634
Abstract:
This invention provides for efflux pump inhibitors to be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens, novel efflux pump inhibitors, combined dosage forms of efflux pump inhibitors with an antimicrobial, and novel medical methods.

Minicells Displaying Antibodies Or Derivatives Thereof And Comprising Biologically Active Compounds

View page
US Patent:
8101396, Jan 24, 2012
Filed:
Mar 16, 2007
Appl. No.:
11/725196
Inventors:
Roger A. Sabbadini - Lakeside CA, US
Neil Berkley - San Diego CA, US
Mark W. Surber - San Diego CA, US
Robert Klepper - San Diego CA, US
Assignee:
Vaxiion Therapeutics, Inc. - San Diego CA
International Classification:
C12N 1/12
C12N 1/20
US Classification:
4352521, 4352523
Abstract:
Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.

Immunogenic Minicells And Methods Of Use

View page
US Patent:
8129166, Mar 6, 2012
Filed:
Jun 4, 2008
Appl. No.:
12/133308
Inventors:
Roger A. Sabbadini - Lakeside CA, US
Neil Berkley - San Diego CA, US
Mark Surber - San Diego CA, US
Assignee:
Vaxiion Therapeutics, Inc. - San Diego CA
International Classification:
C12N 1/21
C12N 15/00
US Classification:
4352523, 4353201
Abstract:
The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.
Control profile
Mark William Surber from San Diego, CA, age ~56 Get Report